Skip to main content
1499 search results for:

Antiparkinsonian Drugs 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-01-2023 | Deep Brain Stimulation | News

    Antiparkinsonian drugs

    Lack of efficacy: case report
  2. 01-04-2019 | Thrombocytopenia | News

    Antiparkinsonian drugs withdrawal

    Neuroleptic malignant-like syndrome causing thrombocytopenia following drug withdrawal: case report
  3. 01-01-2019 | Polyneuropathy | News

    Antiparkinsonians drugs

    Vitamin B6 deficiency and periphery axonal polyneuropathy: 3 case reports
  4. Open Access 01-12-2017 | OriginalPaper

    Parkinsonism-hyperpyrexia syndrome after withdrawal of antiparkinsonian drugs and deep brain stimulation surgery

    Parkinsonism-hyperpyrexia syndrome (PHS) is a rare but potentially fatal condition in patients with Parkinson’s disease (PD) and is manifested by pyrexia, muscle rigidity, a reduced level of consciousness, and autonomic instability. It is …

  5. 01-01-2004 | Abstract

    Combined antiparkinsonian drugs increase cardiovascular dysfunction

  6. 01-05-1997 | Abstract

    Treating neuropsyhiatric adverse effects of antiparkinsonian drugs

  7. 01-05-1997 | ReviewPaper

    Neuropsychiatric Adverse Effects of Antiparkinsonian Drugs

    Characteristics, Evaluation and Treatment

    Parkinson’s disease (PD) is a progressive neurological condition that causes considerable disability in the elderly. Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most …

  8. 01-10-2003 | OriginalPaper

    Use of antiparkinsonian drugs in the Umbria Region

    Discussion of differences between recommended guidelines and clinical practice is very useful in medicine. The use of a computerized database of all prescriptions of antiparkinsonian drugs enabled us to perform an epidemiological population-based …

  9. 01-04-2000 | OriginalPaper

    Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms

    Motor dysfunction produced by the chronic non-physiological stimulation of dopaminergic receptors on striatal medium spiny neurons is associated with alterations in the sensitivity of glutamatergic receptors, including those of the …

  10. 01-08-2001 | Legacy

    Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease

    Aim: The aim of this study was to determine whether use of antiparkinsonian drugs in pharmacy records can be used as a marker for patients with Parkinson's disease (PD). Method: Data were obtained from the Rotterdam Study, a community‐based …

  11. 01-10-2004 | OriginalPaper

    Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa treatment?

    Introduction: Antiparkinsonian drugs can induce behavioural disturbances, which should be treated by first reducing antiparkinsonian drugs and/or starting a benzodiazepine. If this approach fails, then antipsychotics can be considered. The aim of …

  12. 17-04-2024 | Parkinson's Disease | News | Article

    Better motor control with subcutaneous levodopa–carbidopa

    People with Parkinson's disease gain more daily hours without dyskinesia with subcutaneous infusion of a levodopa–carbidopa solution than with oral levodopa–carbidopa.

  13. Open Access 08-04-2024 | Parkinson's Disease | OriginalPaper

    On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis

    Parkinson’s disease (PD) is associated with the development of psychosis (PDP), including hallucinations and delusions, in more than half of the patient population. Optimal PD management must therefore involve considerations about both motor and …

  14. Open Access 01-12-2024 | Parkinson's Disease | OriginalPaper

    Medication adherence and costs of medical care among patients with Parkinson’s disease: an observational study using electronic medical records

    Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease globally, affecting adults 65 and older [ 1 ]. With an aging population, the disability-adjusted life years for PD more than doubled globally between 1990 and 2016 [ 2 …

  15. 25-05-2024 | Online First

    From lab bench to hope: a review of gene therapies in clinical trials for Parkinson’s disease and challenges

    Parkinson's disease (PD) is a chronic neurological disorder that is identified by a characteristic combination of symptoms such as bradykinesia, resting tremor, rigidity, and postural instability. It is the second most common neurodegenerative …

  16. 06-01-2024 | Levodopa | OriginalPaper

    Kinect-based objective assessment of the acute levodopa challenge test in parkinsonism: a feasibility study

    The acute levodopa challenge test (ALCT) has been widely used in the field of parkinsonism [ 1 ]. A clinically significant levodopa response in ALCT, which is defined as the improvement rate (IR, which indicates the change in value before and after …

  17. 05-04-2024 | Amantadine | Online First

    Amantadine use in the French prospective NS-Park cohort

    Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Its prevalence is expected to double by 2040 (14 million patients worldwide) (Dorsey et al. 2018 ). Many medications are available to treat PD, the most effective one …

  18. Open Access 01-12-2024 | ReviewPaper

    Cognitive disorders in advanced Parkinson’s disease: challenges in the diagnosis of delirium

    Parkinson’s disease (PD) is a neurodegenerative condition that is frequently associated with cognitive disorders. These can arise directly from the primary disease, or be triggered by external factors in susceptible individuals due to PD or other …

  19. Open Access 01-12-2024 | Parkinson's Disease | OriginalPaper

    Evaluation of peripheral and autonomic nervous systems dysfunctions in patients with Parkinson’s disease

    Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons and manifested by motor and non-motor symptoms including cognitive problems, dysfunction of the autonomic nervous system …

  20. 04-05-2024 | Online First

    Postural Stability and Gait in Parkinson’s Disease

    This review examines the current state of the problem of movement disorders in Parkinson’s disease (PD). The most difficult issues – objective diagnosis and treatment and rehabilitation of patients with PD with postural instability – are …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.